Synmosa Biopharma Corporation

TPEX:4114 Stock Report

Market Cap: NT$14.0b

Synmosa Biopharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chih-Hui Lin

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure19.8yrs
CEO ownership1.0%
Management average tenureno data
Board average tenure5.8yrs

Recent management updates

Recent updates

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Apr 04
Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Mar 08
If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 31
Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05
Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 09
Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

CEO Compensation Analysis

How has Chih-Hui Lin's remuneration changed compared to Synmosa Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

NT$718m

Jun 30 2024n/an/a

NT$689m

Mar 31 2024n/an/a

NT$650m

Dec 31 2023n/an/a

NT$595m

Sep 30 2023n/an/a

NT$585m

Jun 30 2023n/an/a

NT$562m

Mar 31 2023n/an/a

NT$800m

Dec 31 2022n/an/a

NT$799m

Sep 30 2022n/an/a

NT$735m

Jun 30 2022n/an/a

NT$693m

Mar 31 2022n/an/a

NT$368m

Dec 31 2021n/an/a

NT$304m

Sep 30 2021n/an/a

NT$288m

Jun 30 2021n/an/a

NT$293m

Mar 31 2021n/an/a

NT$634m

Dec 31 2020NT$5mNT$4m

NT$638m

Compensation vs Market: Insufficient data to establish whether Chih-Hui's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Insufficient data to compare Chih-Hui's compensation with company performance.

CEO

Chih-Hui Lin (41 yo)

19.8yrs

Tenure

NT$4,710,000

Compensation

Mr. Chih-Hui Lin serves as Chairman at Synmosa Biopharma Corporation and serves as its Director since May 16, 2019. He serves as President, Managerial officer and General Manager of the Synmosa Biopharma C...

Board Members

NamePositionTenureCompensationOwnership
Chih-Hui Lin
Chairman19.8yrsNT$4.71m1.02%
NT$ 143.2m
San-Chien Tu
Additional Independent Director1.6yrsno datano data
Xiang-Lang Liu
Independent Director22.1yrsNT$1.07mno data
Xiu-Mei Lin
Independent Director5.8yrsNT$1.19m0.0011%
NT$ 150.2k
You-Peng Zhang
Representative Director5.8yrsNT$1.09m1.01%
NT$ 141.3m
Li-Wen Huang
Representative Director16yrsNT$1.09m0.92%
NT$ 129.6m
Huilan Qiu
Independent Director1yrno data1.92%
NT$ 269.0m
Hui-Lan Qiu
Director1yrno datano data

5.8yrs

Average Tenure

42yo

Average Age

Experienced Board: 4114's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 10:15
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Synmosa Biopharma Corporation is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xiaowei HuangMasterlink Securities Corp.
Yijun ChenSinoPac Securities Investment Service